Volume 13, Issue 2 (6-2025)                   JoMMID 2025, 13(2): 111-117 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Khan R, Zahoor D, Farhana A, Jehan M. Clinical Characteristics, Breakthrough Infections, and Reinfections with SARS-CoV-2 among Healthcare Workers in the Omicron Wave. JoMMID 2025; 13 (2) :111-117
URL: http://jommid.pasteur.ac.ir/article-1-686-en.html
Clinical Characteristics, Breakthrough Infections, and Reinfections with SARS-CoV-2 among Healthcare Workers in the Omicron Wave
Reyaz Khan * , Danish Zahoor , Anjum Farhana , Masarat Jehan
Department of Microbiology, Government Medical College, Srinagar, Jammu & Kashmir, India
Abstract:   (89 Views)
Introduction: A global increase in infections was noted with the emergence of the Omicron variant, which exhibited immune evasion capabilities against previous infections or vaccinations. Healthcare workers (HCWs) faced increased risk from occupational exposure. This study aimed to investigate the clinical characteristics, reinfection rates, and breakthrough infections among HCWs during the Omicron wave. Methods:  A total of 312 HCWs who tested positive for SARS-CoV-2 during the Omicron wave (January 1–February 22, 2022) were enrolled in the study after providing consent. Participating HCWs completed a questionnaire to provide details on demographics, symptoms at testing, comorbidities, vaccination status, and prior COVID-19 infection history. Clinical outcomes were also recorded. Cases of reinfection and breakthrough infection were identified. Results: The median age of HCWs in the study was 32.9 years. The frequency of infection was higher in females (56.7%) and among the professional categories, doctors (58.3%) accounted for the majority of cases. Symptomatic infection was prevalent in 89.7% of cases, with most being mild. Out of 312 healthcare workers, 265 (84.9%) received at least one dose of the Covishield vaccine. Of these, 206 (77.7%) received two doses, and 41 (15.5% of vaccinated HCWs) also received a booster dose. 153 (49.1%) had a history of prior SARS-CoV-2 infection. Hospitalization was required for three unvaccinated HCWs with comorbidities, while no vaccinated HCWs required hospitalization; no deaths occurred. Conclusions: The study found that 312 healthcare workers were infected during the Omicron wave. Vaccination and prior infection did not provide complete protection against the Omicron variant. Consequently, breakthrough infections and reinfections were observed with notable frequency during this period.

 
Keywords: Omicron variant, Reinfection, Breakthrough infection, Covishield vaccination, Healthcare workers
Full-Text [PDF 841 kb]   (13 Downloads)    
Type of Study: Original article | Subject: Other
Received: 2024/09/27 | Accepted: 2025/06/11 | Published: 2025/06/11
References
1. Kurhade C, Zou J, Xia H, Liu M, Chang HC, Ren P, et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med. 2023; 29 (2): 344-7. [DOI:10.1038/s41591-022-02162-x] [PMID]
2. World Health Organization. Enhancing response to Omicron (COVID-19 variant B.1.1.529): technical brief and priority actions for Member States [Internet]. Geneva: World Health Organization; 2022 Jan 7 [cited 2025 Mar 10]. Available from: https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states.
3. World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern [Internet]. Geneva: World Health Organization; 2021 Nov 26 [cited 2025 Mar 10]. Available from: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.
4. Shervani Z, Bhardwaj D, Hasan S, Qazi UY, Purang M, Ibbrahim A, et al. The Omicron Wave in India, Mumbai, and Delhi: prevalence and pathogenicity. Eur J Med Health Sci. 2022; 4 (3): 123-30. [DOI:10.24018/ejmed.2022.4.3.1376]
5. Karyakarte RP, Das R, Dudhate S, Agarasen J, Pillai P, Chandankhede PM, et al. Clinical characteristics and outcomes of laboratory-confirmed SARS-CoV-2 cases infected with Omicron subvariants and the XBB recombinant variant. Cureus. 2023; 15 (2): e35261. [DOI:10.1101/2023.01.05.23284211]
6. Abdool Karim SS, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021; 398 (10317): 2126-8. [DOI:10.1016/S0140-6736(21)02758-6] [PMID]
7. Nair C, Kozak R, Alavi N, Mbareche H, Kung RC, Murphy KE, et al. Evaluation of real and perceived risk to health care workers caring for patients with the Omicron variant of the SARS-CoV-2 virus in surgery and obstetrics. J Obstet Gynaecol Can. 2024; 46 (3): 102276. [DOI:10.1016/j.jogc.2023.102276] [PMID]
8. Malhotra S, Mani K, Lodha R, Bakhshi S, Mathur VP, Gupta P, et al. COVID-19 infection, and reinfection, and vaccine effectiveness against symptomatic infection among health care workers in the setting of Omicron variant transmission in New Delhi, India. Lancet Reg Health Southeast Asia. 2022; 3: 100023. [DOI:10.1016/j.lansea.2022.100023] [PMID] [PMCID]
9. Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021; 373: n1088. [DOI:10.1136/bmj.n1088] [PMID] [PMCID]
10. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021; 397 (10286): 1725-35. [DOI:10.1016/S0140-6736(21)00790-X] [PMID]
11. Link-Gelles R, Ciesla AA, Roper LE, Scobie HM, Ali AR, Miller JD, et al. Early estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to Omicron BA.5- and XBB/XBB.1.5-related sublineages among immunocompetent adults-increasing community access to testing program, United States, December 2022-January 2023. MMWR Morb Mortal Wkly Rep. 2023; 72 (5): 119-24. [DOI:10.15585/mmwr.mm7205e1] [PMID] [PMCID]
12. Yahav D, Yelin D, Eckerle I, Eberhardt CS, Wang J, Cao B, et al. Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. Clin Microbiol Infect. 2021; 27 (3): 315-8. [DOI:10.1016/j.cmi.2020.11.028] [PMID] [PMCID]
13. CDC COVID-19 Vaccine Breakthrough Case Investigations Team. COVID-19 vaccine breakthrough infections reported to CDC - United States, January 1-April 30, 2021. MMWR Morb Wkly Rep. 2021; 70 (21): 792-3. [DOI:10.15585/mmwr.mm7021e3] [PMID] [PMCID]
14. Karmacharya A, Rai K, Siwakoti S, Khanal B, Bhattarai NR. COVID-19 breakthrough infections in vaccinated individuals at BPKIHS, Nepal. BMC Infect Dis. 2024; 24 (1): 1003. [DOI:10.1186/s12879-024-09902-z] [PMID] [PMCID]
15. World Health Organization. Health worker exposure risk assessment and management in the context of COVID-19 virus: interim guidance, 4 March 2020. Geneva: WHO; 2020. Report No.: WHO/2019-nCoV/HCW_Surveillance_Protocol/2020.1
16. Maria LD, Sponselli S, Caputi A, Stefanizzi P, Pipoli A, Giannelli G, et al. SARS-CoV-2 breakthrough infections in health care workers: an Italian retrospective cohort study on characteristics, clinical course and outcomes. J Clin Med. 2023; 12 (2): 628. [DOI:10.3390/jcm12020628] [PMID] [PMCID]
17. Cegolon L, Ronchese F, Ricci F, Negro C, Larese-Filon F. SARS-CoV-2 infection in health care workers of Trieste (North-Eastern Italy), 1 October 2020-7 February 2022: occupational risk and the impact of the Omicron variant. Viruses. 2022; 14 (8): 1663. [DOI:10.3390/v14081663] [PMID] [PMCID]
18. Sheng WH, Chang HC, Chang SY, Hsieh MJ, Chen YC, Wu YY, et al. SARS-CoV-2 infection among healthcare workers who already received booster vaccination during epidemic outbreak of Omicron variant in Taiwan. J Formos Med Assoc. 2023; 122 (5): 376-83. [DOI:10.1016/j.jfma.2022.12.003] [PMID] [PMCID]
19. Rahman S, Rahman MM, Miah M, Begum MN, Sarmin M, Mahfuz M, et al. COVID-19 reinfections among naturally infected and vaccinated individuals. Sci Rep. 2022; 12 (1): 1438. [DOI:10.1038/s41598-022-05325-5] [PMID] [PMCID]
20. Yassa M, Graber JM, Black K, Resende ADSD, Legard A, Caruth J. Comparison of COVID-19 symptoms in correctional health care workers during the initial and Omicron surges. J Correct Health Care. 2024; 30 (3): 158-66. [DOI:10.1089/jchc.23.09.0072] [PMID]
21. Evans RA, Dube S, Lu Y, Yates M, Arnetorp S, Barnes E, et al. Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study. Lancet Reg Health Eur. 2023; 35: 100747. [DOI:10.1016/j.lanepe.2023.100747] [PMID] [PMCID]
22. Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, et al. Protection against SARS-CoV-2 after COVID-19 vaccination and previous infection. N Engl J Med. 2022; 386 (13): 1207-20. [DOI:10.1056/NEJMoa2118691] [PMID] [PMCID]
23. Cai C, Li Y, Hu T, Liang R, Wang K, Guo C, et al. The associated factors of SARS-CoV-2 reinfection by Omicron variant - Guangdong Province, China, December 2022 to January 2023. China CDC Wkly. 2023; 5 (18): 391-6. [DOI:10.46234/ccdcw2023.075] [PMID] [PMCID]
24. Akhter M, Roy SK, Khair A, Karim MR, Mojlish UKFK, Ahmed MU, et al. SARS-COV-2 breakthrough infection and its covariates among healthcare providers of a hospital in Bangladesh during the Omicron wave. Heliyon. 2024; 10 (17): e37287. [DOI:10.1016/j.heliyon.2024.e37287] [PMID] [PMCID]
25. Gidari A, Sabbatini S, Bastianelli S, Pierucci S, Busti C, Svizzeretto E, et al. Tixagevimab/cilgavimab: still a valid prophylaxis against COVID-19 new variants? Viruses. 2024; 16 (3): 354. [DOI:10.3390/v16030354] [PMID] [PMCID]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.